Leproust Emily M. sold $919K of TWST
Leproust Emily M. (Chief Executive Officer) sold 4,548 shares of Twist Bioscience Corp (TWST) at an average of $202.15 ($200.44–$207.46, $0.92M total) across 8 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh, material information about insider activity, but the amount is modest relative to the company's market cap.
Market read
The filing offers a new data point for traders monitoring insider activity; likely limited price impact.
What to watch
Potential upcoming financing needs or personal tax planning could be driving the sale.
Background
Form 4 filings disclose insider transactions; the CEO used a pre‑arranged 10b5‑1 plan to sell shares.
Ticker impact
CEO Emily Leproust sold $919K of TWST shares via a 10b5-1 plan, reducing her holdings to 562,760 shares.
likely slight downward pressure as the market prices in the insider sell.
Form 4 filings are primary disclosures; a $919K sale by the CEO is material enough to affect short‑term sentiment.
Market effects
Minimal impact on the synthetic biology sector; insider sales are routine.
No broader regional effect.
Limited to investors tracking TWST.
Counterpoint
The sale could be a routine liquidity event and not indicative of negative outlook.
Key entities
- personEmily M. Leproust
Chief Executive Officer of Twist Bioscience Corp.
- companyTwist Bioscience Corp
Biotechnology company listed on NASDAQ under ticker TWST.
